

8
DWT
5-14-03Docket No.: PF454P2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gentz et al

Application No.: 09/935,727

Group Art Unit: 1646

Filed: August 24, 2001

Examiner: E. O'Hara

For: Tumor Necrosis Factor Receptors 6 Alpha & 6
Beta

Official
5/13/03
GAINFORMATION DISCLOSURE STATEMENT (IDS)Commissioner for Patents
Washington, DC 20231

Dear Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-DN listed on the attached Form PTO/SB/08A. A copy of each of references CF-DN is enclosed.

Copies of references AA-CE were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 09/518,931, filed March 3, 2000, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the above-listed file for copies of references AA-CE.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR §§ 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Application No.: 09/935,727

Docket No.: PF454P2

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Dated: December 16, 2002

Respectfully submitted,

By 

Kenley K. Hoover

Registration No.: 40,302

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue

Rockville, Maryland 20850

(301) 610-5771

Attorney for Applicant